-
2023-504031-41-00
5
2024-03-25
ER+/HER2- Early Breast Cancer
-
2022-501453-36-00
5
2024-02-23
Breast cancer
-
2024-517363-24-00
4
2024-02-16
Advanced FIGO Stage III‐IV High Grade Serous or Endometrioid Ovarian,
-
2022-501904-83-00
7
2023-09-11
Ovarian Cancer
-
2024-513562-19-00
5
2023-08-30
End-Stage Kidney Disease
-
2022-500587-35-01
5
2023-07-06
Stroke
-
2024-514826-22-00
7
2022-12-05
Part A: Patients with advanced solid tumors or lymphomas.
-
2024-514139-50-00
5
2022-11-14
Multiple myeloma
-
2023-507699-38-00
5
2022-08-30
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
-
2024-518242-24-00
5
2022-06-27
Chronic liver disease
-
2023-507029-40-00
5
2022-05-09
Genetic carriers of dilated cardiomyopathy causing variants
-
2022-502425-18-00
5
2022-04-19
Adenocarcinoma of the prostate
-
2023-505438-85-00
5
2022-01-12
Acute myocardial infarction (AMI)
-
2023-508002-20-00
7
2021-10-21
advanced, solid, relapsed tumors / advanced tumors: human lymphomas /
-
2024-512671-12-00
10
2021-03-05
Unresectable head and neck squamous cell carcinoma, metastatic head an
-
2024-510783-23-00
7
2020-10-29
Fallopian Tube Cancer
-
2024-513734-38-00
5
2019-07-03
Prevention of breast cancer in women with a BRCA1 germline mutation
-
2022-502706-33-00
6
2018-01-10
Patients with invasive breast cancer in early stages
-
2024-513511-27-00
4
2025-05-29
HR-negative/HER2-negative resectable stage I TNBC.
-
2024-512998-27-00
5
2025-02-21
Non-Small Cell Lung Cancer
-
2024-510719-31-00
5
2025-01-24
Moderate to Severe Vasomotor Symptoms (VMS)
-
2024-513952-13-00
5
2025-01-02
HR+ / HER2- advanced breast cancer
-
2024-514728-17-00
11
2024-12-30
Advanced or recurrent endometrial cancer
-
2024-510648-29-00
10
2024-12-12
Patients diagnosed with acute myeloid leukemia (AML) with persistent m